2023
Defining Priorities in Value-Based Cancer Care: Insights From the Alliance for Clinical Trials in Oncology National Cooperative Group Survey
Allen C, Snyder R, Horn D, Hudson M, Barber A, Smieliauskas F, Spears P, Edge S, Greenup R. Defining Priorities in Value-Based Cancer Care: Insights From the Alliance for Clinical Trials in Oncology National Cooperative Group Survey. JCO Oncology Practice 2023, 19: 932-938. PMID: 37651652, PMCID: PMC10615548, DOI: 10.1200/op.23.00159.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesInclusion of PROsQuality of lifePatients' QOLClinical trialsHealth care systemHealth system performanceCancer CenterCancer-related health care costsCare systemTherapeutic assessmentAcademic cancer centerEvidence-based careCancer clinical trialsDirect patient careHealth care costsNational Cancer InstituteOncologic outcomesOverall survivalMedical oncologistsCancer careOncology practiceCancer InstituteNonphysician providersCare costs
2020
The effect of body mass index (BMI) on survival in patients with breast cancer and obesity-associated conditions.
Caddell K, Ren Y, Sampathkumar A, Almond C, Ladipo O, Champ C, Rosenberger L, Greenup R, Plichta J, DiLalla G, Menendez C, Tolnitch L, Hwang E, Hyslop T, Fayanju O. The effect of body mass index (BMI) on survival in patients with breast cancer and obesity-associated conditions. Journal Of Clinical Oncology 2020, 38: 203-203. DOI: 10.1200/jco.2020.38.29_suppl.203.Peer-Reviewed Original ResearchBody mass indexObesity-associated conditionsUnadjusted overall survivalClass 1 obesityOverall survivalBreast cancer outcomesBreast cancerWorse OSObese patientsOverweight womenMass indexBMI classesCancer outcomesAssociation of BMIEffect of BMINon-Hispanic black womenKaplan-Meier methodNormal-weight womenDiagnosis of obesityProportional hazards modelBreast cancer diagnosisStage 0Hazards modelHypertensionObesityPathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
Spring L, Fell G, Arfe A, Sharma C, Greenup R, Reynolds K, Smith B, Alexander B, Moy B, Isakoff S, Parmigiani G, Trippa L, Bardia A. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clinical Cancer Research 2020, 26: 2838-2848. PMID: 32046998, PMCID: PMC7299787, DOI: 10.1158/1078-0432.ccr-19-3492.Peer-Reviewed Original ResearchConceptsPathologic complete responseEvent-free survivalBetter event-free survivalNeoadjuvant chemotherapyAdjuvant chemotherapyOverall survivalComplete responseBreast cancerImproved event-free survivalIndividual patient-level dataAdditional adjuvant therapySubsequent adjuvant chemotherapyBreast cancer recurrencePatient-level dataComprehensive Meta-AnalysisAdjuvant settingNeoadjuvant responseAdjuvant therapyMicrometastatic diseaseImproved survivalPrognostic significanceSystemic clearanceCancer recurrenceInclusion criteriaChemotherapyMissing data in breast cancer: Relationship with survival in national databases.
Plichta J, Rushing C, Lewis H, Blazer D, Hyslop T, Greenup R. Missing data in breast cancer: Relationship with survival in national databases. Journal Of Clinical Oncology 2020, 38: e19114-e19114. DOI: 10.1200/jco.2020.38.15_suppl.e19114.Peer-Reviewed Original ResearchOverall survivalNational Cancer RegistryTumor variablesCancer RegistryBreast cancerLarge national cancer registryCox proportional hazards modelInvasive breast cancerPatterns of careInclusion/exclusion criteriaTreatment variablesProportional hazards modelRate of deathWorse OSOncology outcomesN stageOS differenceExclusion criteriaOutcome studiesHazards modelPatientsNCDBSurgery dataGreater riskNational database
2019
Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma
Thornton M, Williamson H, Westbrook K, Greenup R, Plichta J, Rosenberger L, Gupta A, Hyslop T, Hwang E, Fayanju O. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma. Annals Of Surgical Oncology 2019, 26: 3166-3177. PMID: 31342392, PMCID: PMC6736696, DOI: 10.1245/s10434-019-07564-9.Peer-Reviewed Original ResearchConceptsNeoadjuvant endocrine therapyInvasive lobular carcinomaOverall survivalEndocrine therapyLobular carcinomaHormone receptor-positive groupNational Cancer Data BaseLower ratesPathologic complete responseKaplan-Meier curvesReceptor-positive groupCox proportional hazardsBackgroundNeoadjuvant chemotherapyCN1-3More comorbiditiesPostmastectomy radiationNeoadjuvant chemotherapyNeoadjuvant therapyComplete responseClinical trialsBreast cancerCT classificationSmall tumorsProportional hazardsGreater burden
2018
The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT)
Fayanju O, Ren Y, Thomas S, Greenup R, Plichta J, Rosenberger L, Tamirisa N, Force J, Boughey J, Hyslop T, Hwang E. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT). Annals Of Surgery 2018, 268: 591-601. PMID: 30048319, PMCID: PMC6496955, DOI: 10.1097/sla.0000000000002953.Peer-Reviewed Original ResearchConceptsPathologic complete responseImproved overall survivalNeoadjuvant chemotherapyOverall survivalComplete responseBreast cancerHuman epidermal growth factor receptor 2 (HER2) statusEpidermal growth factor receptor 2 statusCox proportional hazards modelHormone receptorsNode-positive patientsTriple-negative diseaseKaplan-Meier curvesBreast cancer patientsMultivariate logistic regressionProportional hazards modelAnatomic extentCancer patientsReceptor subtypesClinical significanceHazards modelTumor subtypesPatientsBreastLogistic regressionAxillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival
Tamirisa N, Thomas S, Fayanju O, Greenup R, Rosenberger L, Hyslop T, Hwang E, Plichta J. Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival. Annals Of Surgical Oncology 2018, 25: 2890-2898. PMID: 29968029, PMCID: PMC6404232, DOI: 10.1245/s10434-018-6595-2.Peer-Reviewed Original ResearchConceptsBreast cancer patientsElderly breast cancer patientsCN0 breast cancerOverall survivalNodal surgeryCancer patientsAxillary surgeryElderly patientsTreatment decisionsBreast cancerCharlson-Deyo comorbidity scoreCN0 breast cancer patientsSurgical lymph node evaluationCox proportional hazards modelAdjuvant therapy decisionsAdjuvant therapy receiptAxillary nodal evaluationLymph node evaluationNational Cancer DatabaseYear of diagnosisWorse overall survivalEstrogen receptor statusLong-term outcomesSubsequent treatment decisionsProportional hazards model
2017
Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.
Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes K, Isakoff S, Ellisen L, Smith B, Specht M, Moy B, Bardia A. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. Journal Of The National Comprehensive Cancer Network 2017, 15: 1216-1223. PMID: 28982747, DOI: 10.6004/jnccn.2017.0158.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsFemaleFollow-Up StudiesHumansMutationNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingRecurrenceRegistriesRetrospective StudiesSurvival AnalysisTreatment OutcomeTriple Negative Breast NeoplasmsYoung AdultConceptsPathologic complete responseDisease-free survivalBaseline clinical stageNeoadjuvant chemotherapyOverall survivalBreast cancerYoung womenComplete responseClinical stageResidual diseaseInvasive breast cancerLong-term outcomesAggressive tumor biologyMassachusetts General HospitalDFS ratesNeoadjuvant therapyOS ratesSurvival outcomesSurrogate markerGeneral HospitalBest therapyHigh riskTrial designRapid triagePatientsThe epidemiology of metaplastic breast cancer: A review of 2,500 cases from the national cancer database.
Campbell B, Thomas S, Ong C, Greenup R, Plichta J, Rosenberger L, Force J, Hyslop T, Hwang E, Fayanju O. The epidemiology of metaplastic breast cancer: A review of 2,500 cases from the national cancer database. Journal Of Clinical Oncology 2017, 35: 1570-1570. DOI: 10.1200/jco.2017.35.15_suppl.1570.Peer-Reviewed Original ResearchMetaplastic breast cancerNational Cancer DatabaseTriple-negative breast cancerMBC patientsBreast cancerMBC diagnosisReceptor statusCancer DatabaseAcademic centersSociodemographic factorsHigher clinical T stageFemale breast cancer patientsAdult female breast cancer patientsClinical T stageClinical N stageBreast cancer patientsMultivariate logistic regressionPopulation-based analysisCox proportional hazardsGovernment-sponsored insuranceNon-Hispanic blacksLow socioeconomic statusPaucity of dataOverall survivalWorse survivalA population-based analysis of treatment and outcomes in 2,500 metaplastic breast cancer patients.
Ong C, Thomas S, Campbell B, Greenup R, Plichta J, Rosenberger L, Force J, Hyslop T, Hwang E, Fayanju O. A population-based analysis of treatment and outcomes in 2,500 metaplastic breast cancer patients. Journal Of Clinical Oncology 2017, 35: 532-532. DOI: 10.1200/jco.2017.35.15_suppl.532.Peer-Reviewed Original ResearchMetaplastic breast cancerMBC patientsOverall survivalWorse OSHigher clinical T stageMetaplastic breast cancer patientsCox proportional hazards modelNational Cancer DatabaseClinical T stageBreast cancer patientsPopulation-based analysisProportional hazards modelAxillary dissectionTN patientsReceptor statusTN subtypeAggressive variantHigher proportionLuminal subtypeT stageTreatment patternsEntire cohortKaplan-MeierCancer patientsSubgroup analysisImpact of insurance status on treatment for stage 0-IV breast cancer.
Greenup R, Thomas S, Fayanju O, Hyslop T, Hwang E. Impact of insurance status on treatment for stage 0-IV breast cancer. Journal Of Clinical Oncology 2017, 35: 6532-6532. DOI: 10.1200/jco.2017.35.15_suppl.6532.Peer-Reviewed Original ResearchRisk of deathInsurance statusBreast cancerStage 0Private insuranceMultivariate Cox proportional hazards modelStage 1 breast cancerUninsured breast cancer patientsNational Cancer Data BaseCox proportional hazards modelUnilateral stage 0Receipt of chemotherapyReceipt of surgeryStage 4 diseaseReceipt of treatmentBreast cancer patientsProportional hazards modelBinary logistic regressionNeoadjuvant chemotherapyOncologic outcomesOverall survivalBilateral mastectomyMedian ageUninsured womenTreatment patternsRole of axillary node dissection after mastectomy with positive sentinel nodes.
Park T, Thomas S, Greenup R, Hwang E. Role of axillary node dissection after mastectomy with positive sentinel nodes. Journal Of Clinical Oncology 2017, 35: 554-554. DOI: 10.1200/jco.2017.35.15_suppl.554.Peer-Reviewed Original ResearchAxillary lymph node dissectionPositive sentinel nodesAdjuvant radiationNode dissectionSentinel nodesTumor sizeRadiation treatmentComparable overall survivalLymph node dissectionMedian tumor sizeNational Cancer DatabaseStage IV diseaseAxillary node dissectionBreast conservation therapyHazard of deathAxillary lymphadenectomyPositive SLNZ11 trialCause mortalityEndocrine therapyNeoadjuvant chemotherapyPositive nodesNegative patientsOverall survivalSentinel lymphTemporal associations between prognostic indicators and overall survival after breast cancer.
Plichta J, Thomas S, Fayanju O, Rosenberger L, Park T, Hyslop T, Greenup R, Hwang E. Temporal associations between prognostic indicators and overall survival after breast cancer. Journal Of Clinical Oncology 2017, 35: e18144-e18144. DOI: 10.1200/jco.2017.35.15_suppl.e18144.Peer-Reviewed Original ResearchOverall survivalReduced overall survivalEndocrine therapyBreast cancerNon-metastatic invasive breast cancerAssociation of OSHormone receptorsTreatment factorsInvasive breast cancerLong-term outcomesInvasive ductal carcinomaMultivariate survival analysisUnderwent lumpectomyTerm outcomesDuctal carcinomaPrognostic indicatorMultiple time pointsBreast oncologistsSurvival analysisChemotherapyTime pointsTumorsCT/Temporal associationSurvival
2015
Trends in Treatment Patterns and Outcomes for Ductal Carcinoma in Situ
Worni M, Akushevich I, Greenup R, Sarma D, Ryser M, Myers E, Hwang E. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma in Situ. Journal Of The National Cancer Institute 2015, 107: djv263. PMID: 26424776, PMCID: PMC4707192, DOI: 10.1093/jnci/djv263.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingConfounding Factors, EpidemiologicDisease-Free SurvivalFemaleHumansMastectomyMastectomy, Modified RadicalMastectomy, SegmentalMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioProportional Hazards ModelsRadiotherapy, AdjuvantReceptors, EstrogenReceptors, ProgesteroneSEER ProgramSentinel Lymph Node BiopsySurvival AnalysisTreatment OutcomeUnited StatesConceptsOverall survivalTreatment patternsPre-invasive breast cancerSentinel lymph node biopsyCox proportional hazards regressionLocoregional treatment optionsNational treatment trendsEnd Results registryLymph node biopsyBreast cancer outcomesLong-term outcomesProportional hazards regressionPatient selection biasCochran-Armitage trend testInverse probability weightsDCIS patientsNode biopsyBilateral mastectomyDuctal carcinomaHazards regressionCancer outcomesTreatment optionsBreast cancerTreatment trendsLumpectomy
2012
Association of pathologic complete response following neoadjuvant chemotherapy with survival among young women with breast cancer.
Greenup R, Bardia A, Buckley J, Niemierko A, Camp M, Coopey S, Gadd M, Schapira L, Taghian A, Smith B, Specht M. Association of pathologic complete response following neoadjuvant chemotherapy with survival among young women with breast cancer. Journal Of Clinical Oncology 2012, 30: 1122-1122. DOI: 10.1200/jco.2012.30.15_suppl.1122.Peer-Reviewed Original ResearchPathologic complete responseNeoadjuvant chemotherapyOverall survivalBreast cancerComplete responseYoung womenAdjuvant chemotherapyHazard ratioHER-2Stage IYoung breast cancer patientsTriple-negative breast cancerNeo-adjuvant chemotherapyTiming of chemotherapyBreast cancer patientsState tumor registryFinal pathologic reviewDeath certificate dataNegative breast cancerValuable surrogate markerOS ratesPathologic reviewSystemic therapyTumor RegistryDeath Index